慢性硬膜下血肿的类固醇治疗(SUCRE试验):随机对照试验研究方案
SUCRE试验是一项双盲随机对照试验,比较甲泼尼龙与安慰剂治疗无临床和/或影像学严重征象的慢性硬膜下血肿(CSDH),计划纳入202例(每组101例),每日1 mg/kg治疗3周,主要终点为治疗开始后1个月内需要手术治疗的延迟时间。
要点
- 双盲随机对照试验比较甲泼尼龙与安慰剂治疗无严重征象的CSDH。
- 甲泼尼龙1 mg/kg每日给药,持续3周,计划每组101例。
- 主要终点为治疗开始后1个月内手术治疗的延迟时间。
核心结论
- 该试验结果可能为CSDH患者的管理提供手术之外的有趣替代方案,并可能提供对这一常见病理自然史的见解。
研究设计与样本
- 双盲随机对照试验,比较甲泼尼龙与安慰剂治疗无临床和/或影像学严重征象的慢性硬膜下血肿。
- 计划纳入202例患者(每组101例)。
- 治疗每日给药,剂量1 mg/kg,持续3周。
主要发现
- 主要终点为治疗开始后1个月时手术治疗的延迟发生时间。
- 次要终点包括手术转归率、生存率、生活质量和功能评估、全身性副作用发生以及影像学评估的治疗反应。
- 多模式评估在1、3和6个月时进行。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic subdural hematoma (CSDH) is a common neurological pathology, especially in older patients. The actual "gold standard" of treatment is surgical evacuation, with various techniques used across neurosurgical teams. Over the years, there has been growing evidence that inflammatory processes play a major role in the pathogenesis of CSDH. In that context, the use of corticosteroids has been proposed alone or as an adjuvant treatment to surgery. However, this practice remains very empirical and there is a need for high-quality-of-evidence studies to clarify the role of corticosteroids in the management of CSDH. METHODS/DESIGN: We propose a double-blind, randomized controlled trial comparing methylprednisolone versus placebo in the treatment of CSDH without clinical and/or radiological signs of severity. The treatment will be administered daily for a duration of 3 weeks, at a dose of 1 mg/kg. The primary endpoint will be the delay of occurrence of surgical treatment at 1 month following the introduction of the treatment. Secondary endpoints will include the rate of recourse to surgery, survival rate, quality of life and functional assessments, occurrence of systemic secondary effects and radiological assessment of the response to treatment. This multimodal assessment will be done at 1, 3 and 6 months. Two hundred and two patients (101 per arm) are expected to be included considering our primary hypotheses. DISCUSSION: This trial started in June 2016; its results may open interesting alternatives to surgery in the management of patients harboring a CSDH, and may provide insights into the natural history of this common pathology. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02650609 . Registered on 4 January 2016. Graphical output of the OBF boundaries.
引用
- Henaux PL, Le Reste PJ, Laviolle B, et al. Steroids in chronic subdural hematomas (SUCRE trial): study protocol for a randomized controlled trial. Trials. 2017. PMID: 28583162. doi:10.1186/s13063-017-1990-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。